Sequence: RXRRBRRXRYQFLIRXRBRXRB (X=Ahx, B=β-Ala)
| Experiment Id | EXP001309 |
|---|---|
| Paper | Efficient antisense inhibition reveals microRNA-155 to restrain a late-myeloid inflammatory programm |
| Peptide | Pip6a (Pip CPP) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | no |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | 200 nM |
| Mixing Ratio | |
| Formulation Format | covalent CPP–PNA conjugate |
| Formulation Components | anti-miR-155 PNA sequence: cctatcacgattagcatt; GG linker to CPP |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | primary human blood-derived macrophages (monocyte-derived); PBMC subsets for uptake profiling |
| Animal Model | |
| Administration Route | |
| Output Type | qRT-PCR / RNA-seq miR-155 target de-repression |
| Output Value | No significant de-repression of miR-155 targets at 200 nM (24 h). |
| Output Units | |
| Output Notes | Uptake by FACS (FAM-PNA conjugates): 8% FAM+ macrophages at 200 nM. |
| Toxicity Notes | No relevant cytotoxicity reported in macrophages at 200 nM; no apparent cytotoxicity even at µM concentrations (reported). |
| Curation Notes |